EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DHX15 affects AML1 ‐ ETO9a splicing together with HNRNPL , RBM33 in AML1 ‐ ETO ‐positive acute myeloid leukaemia

Qiao Liu, Xuechun Wang, Jiqiang Fan, Yi Zheng, Luya Ye, Wenhan Chang, Xianglei Chen iD, Yuanhua Cai, Xiaolin Lai, Yang Li, Lili Pan, Xiaofan Li iD und 2 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Qiao Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, F…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, RUNX1 Translocation Partner 1 Protein, Core Binding Factor Alpha 2 Subunit. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Fujian Provincial Department of Science and Technology, National Key Clinical Specialty Discipline Construction Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The AML1‐ETO (AE) fusion gene, resulting from t(8;21)(q22;q22), represents a prevalent subtype of acute myeloid leukaemia (AML). Retention of exon 9a between exon 8 and 9 of the ETO (RUNX1 Partner Transcriptional Co‐Repressor 1, also name RUNX1T1) gene generates the oncogenic AML1‐ETO9a (AE9a) splice variant. Here, we uncover the potential involvement of RNA (ribonucleic acid) helicase DHX15 (DEAH‐box helicase 15) in AE9a splicing and AML progression. Clinically, higher expressed DHX15 is associated with increased AE9a/AE abundance and poor outcomes in AE‐positive (AE + ) AML patients. DHX15 knockdown impaired cell proliferation, induced S/G2 cell‐cycle arrest in vitro and prolonged overall survival in AE + leukaemia‐bearing mice in vivo. In addition, DHX15 knockdown reduced AE and AE9a expression, and RNA immunoprecipitation revealed DHX15 bound to AE and AE9a transcripts and RNA pull‐down assay showed a selective interaction of HNRNPL and RBM33 with AE9a transcripts. Three‐dimensional structure prediction suggests a sophisticated regulatory complex formation involving DHX15, HNRNPL (heterogeneous nuclear ribonucleoprotein L) and RBM33 (RNA binding motif protein 33). Further, HNRNPL and RBM33 gene expression positively correlated with AE9a levels in AE + AML samples. Downregulation of HNRNPL and RBM33 reduced AE9a expression in Kasumi‐1 cells. Collectively, our findings support an association between DHX15, HNRNPL, RBM33 and AE9a splicing and suggest their contribution to leukemogenic progression in AE + AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteOncogene Proteins, FusionRUNX1 Translocation Partner 1 ProteinCore Binding Factor Alpha 2 SubunitRNA-Binding ProteinsDEAD-box RNA HelicasesRNA HelicasesRNA SplicingHumansAnimalsMiceMaleCell Line, Tumor

Stichwörter der Autor:innen

AMLAML1‐ETOAML1‐ETO9aDHX15RNA splicing

Substanzen

Oncogene Proteins, FusionDHX15 protein, humanRUNX1 Translocation Partner 1 ProteinCore Binding Factor Alpha 2 SubunitAML1-ETO fusion protein, humanRNA-Binding ProteinsDEAD-box RNA HelicasesRNA Helicases

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Union Clinical Medical Colleges, Fujian Medical University, Fuzhou, China.
  • School of Life Sciences, Xiamen University, Xiamen, Fujian Province, China.
  • Center for RNA Biology and Therapeutics, Beckman Research Institute of the City of Hope, Duarte, California, USA.
  • Department of Hematology, Weifang Yidu Central Hospital, Qingzhou, Shandong, China.

ORCID-Profile: Xianglei Chen, Xiaofan Li, RenJang Lin

Förderung

  • National Natural Science Foundation of China
  • Fujian Provincial Department of Science and Technology
  • National Key Clinical Specialty Discipline Construction Program of China
  • Fujian Provincial Clinical Research Center for Hematological Malignancies
  • Natural Science Foundation of Fujian Province
  • Fujian Provincial Finance Department

Zitieren

APA

Liu, Q., Wang, X., Fan, J., Zheng, Y., Ye, L., Chang, W., Chen, X., Cai, Y., Lai, X., Li, Y., Pan, L., Li, X., Lin, R., & Wang, S. (2026). DHX15 affects AML1 ‐ ETO9a splicing together with HNRNPL , RBM33 in AML1 ‐ ETO ‐positive acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70658

Vancouver

Liu Q, Wang X, Fan J, Zheng Y, Ye L, Chang W, et al. DHX15 affects AML1 ‐ ETO9a splicing together with HNRNPL , RBM33 in AML1 ‐ ETO ‐positive acute myeloid leukaemia. British Journal of Haematology. 2026. doi:10.1111/bjh.70658

BibTeX
@article{Liu2026,
  author = {Liu, Qiao and Wang, Xuechun and Fan, Jiqiang and Zheng, Yi and Ye, Luya and Chang, Wenhan and Chen, Xianglei and Cai, Yuanhua and Lai, Xiaolin and Li, Yang and Pan, Lili and Li, Xiaofan and Lin, RenJang and Wang, Shaoyuan},
  title = {DHX15 affects AML1 ‐ ETO9a splicing together with HNRNPL , RBM33 in AML1 ‐ ETO ‐positive acute myeloid leukaemia},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70658}
}
Kostenlos starten →